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Abstract
 
Differential display screening was used to reveal differential gene expression between the tu-
morigenic breast cancer cell line CAL51 and nontumorigenic microcell hybrids obtained after
transfer of human chromosome 17 into CAL51. The human profilin 1 (PFN1) gene was found
overexpressed in the microcell hybrid clones compared with the parental line, which displayed
a low profilin 1 level. A comparison between several different tumorigenic breast cancer cell
lines with nontumorigenic lines showed consistently lower profilin 1 levels in the tumor cells.
Transfection of PFN1 cDNA into CAL51 cells raised the profilin 1 level, had a prominent ef-
fect on cell growth, cytoskeletal organization and spreading, and suppressed tumorigenicity of
the stable, PFN1-overexpressing cell clones in nude mice. Immunohistochemical analysis re-
vealed intermediate and low levels of profilin 1 in different human breast cancers. These results
suggest profilin 1 as a suppressor of the tumorigenic phenotype of breast cancer cells.
Key words: tumor suppressor genes • microcell hybrids • cytoskeleton • actin ﬁlament • 
differential display
 
Introduction
 
Previously, we established an experimental system consist-
ing of a tumorigenic breast cancer cell line, CAL51, de-
rived from an invasive adenocarcinoma (1), and several
nontumorigenic CAL51 microcell hybrid clones obtained
after transfer of parts of the human chromosome 17 (2).
We focused on hybrid clone CAL/17-5 containing a trans-
ferred chromosome region 17p13.3 and distal parts of this
chromosome, showing a strongly suppressed neoplastic
phenotype with a clearly reduced growth rate and alter-
ations in cell morphology compared with CAL51 (2).
The significance of the 17p13.3 chromosome region for
tumorigenicity has been demonstrated by the identification
of a candidate tumor suppressor gene, HIC-1 (3), and the
 
discovery of two candidate tumor suppressor genes in
ovarian carcinoma (4) in this region. In addition, reports on
loss of heterozygosity suggest the involvement of at least
one further tumor suppressor gene in the 17p13.3 region
(5). Taken together, this information prompted us to eval-
uate, by differential display (6), altered expression of genes
in our experimental systems.
 
Here, we show that the human profilin 1 (PFN1)
 
1
 
 gene
is expressed at a high level in the microcell hybrid clone
CAL/17-5 and at a much lower level in the breast cancer
cell line CAL51. The chromosomal localization of PFN1 at
17p13.3 (7) is consistent with the chromosomal fragment
transferred into the CAL51 microcell hybrid clones (2).
Profilins are small (14–17 kD) ubiquitous proteins that are
important regulators of F-actin dynamics in cells (8, 9).
Profilins bind monomeric actin (G-actin) and, depending
on the conditions, may either inhibit or promote actin fila-
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ment assembly (10–12). In addition, they bind phospholip-
ids (13, 14) and polyproline motif proteins like formins (15)
and members of the Enabled (Ena)/mammalian Enabled
(Mena)/vasodilator-stimulated phosphoprotein (VASP)
family (16), thus being linked to several signal transduction
pathways. The precise role of profilin in vivo is still under
debate. To correlate the effects of changes in PFN1 expres-
sion with the specific properties of CAL51, we transfected
human PFN1 cDNA into CAL51 cells and isolated deriva-
tive clones expressing different profilin 1 levels. We show
that the sole expression of exogenous PFN1 affects growth,
cytoskeletal organization, cell spreading, and tumorigenic-
ity of CAL51 cells when injected into nude mice. Further-
more, we demonstrate that the profilin 1 level in several
other tumorigenic and nontumorigenic breast epithelial
lines and breast cancer tissue, respectively, correlates with
their transformed state, suggesting a general role for profilin
1 as a tumor suppressor protein.
 
Materials and Methods
 
Cell Culture.
 
The cell line CAL51 (1), its nontumorigenic
microcell hybrid CAL/17-5 (2), and the mock-transfected line
CALX8, were grown in DMEM supplemented with 10% fetal
bovine serum (FBS). For the microcell hybrid and the transfected
cells, the medium was supplemented with 800 
 
m
 
g/ml G418.
Mouse A9(neo17) cells, containing a single human chromosome
17 derived from normal human fibroblasts and tagged with the
neomycin resistance gene (17), were also grown in this medium.
MCF-10A, H184, R30, R103, and T47D cells were grown in
a 1:1 mixture of DMEM and Ham’s F12 medium supple-
mented with 20 ng/ml epidermal growth factor, 100 ng/ml
cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone,
and 5% FBS.
 
RNA Isolation and Differential Display.
 
Total cytoplasmic
RNA from CAL51 and CAL/17-5 cells was isolated from 
 
z
 
10
 
6
 
cells using a standard protocol (18). 2.0 
 
m
 
g total RNA was used
to synthesize first strand cDNAs by Moloney murine leukemia
virus reverse transcriptase (GIBCO BRL) using specific 3
 
9
 
 prim-
ers dT
 
11
 
[A,C,G]N (2.5 
 
m
 
M). Transcription buffer (1
 
3
 
; GIBCO
BRL), dithiothreitol (DTT, 10 
 
m
 
M), dNTPs (20 
 
m
 
M), RNasin
(10 U), and reverse transcriptase (200 U) were added to 20 
 
m
 
l (fi-
nal volume). After incubation at 37
 
8
 
C for 1 h, the reaction was
terminated by incubation at 95
 
8
 
C for 10 min.
The cDNAs were amplified by PCR, using combinations of
the 12 specific 3
 
9
 
 primers and 20 arbitrary 5
 
9
 
 primers according to
the manufacturer’s instructions (Operon). The PCR reaction mix
contained in a final volume of 20 
 
m
 
l: 2 
 
m
 
l first strand cDNA, 3
 
9
 
primer (2 
 
m
 
M), 5
 
9
 
 primer (0.5 
 
m
 
M), dNTPs (2.0 
 
m
 
M), [
 
a
 
-
 
32
 
P]dCTP (6 
 
m
 
Ci), 1
 
3
 
 Taq DNA polymerase reaction buffer,
and Taq DNA polymerase (1.5 U) (PerkinElmer). Reactions
were performed in a PerkinElmer 9600 thermal cycler and con-
sisted of cycles at 95
 
8
 
C for 5 min, followed by 94
 
8
 
C for 30 s,
40
 
8
 
C for 60 s, and 72
 
8
 
C for 30 s for a total of 40 cycles. PCR
products from both cell lines were electrophoretically separated
on a 6% polyacrylamide gel, vacuum-dried at 80
 
8
 
C for 1 h, and
exposed to an x-ray film overnight. Indicated bands were excised
from the gel and eluted in 100 
 
m
 
l TE buffer at 4
 
8
 
C overnight.
Eluted DNA was reamplified by two successive PCRs using the
same conditions as described above. PCR products were run on a
2% agarose gel, visualized by ethidium bromide staining, excised,
 
and purified using the QIAquick Gel Extraction kit (Qiagen).
The purified PCR products were cloned into the pCRII vector,
using the TA Cloning kit according to the manufacturer’s proto-
col (Invitrogen).
 
Northern Blot Analysis.
 
15 
 
m
 
g of total RNA from CAL51 and
CAL/17-5 cells was heat-denatured at 55
 
8
 
C for 15 min, electro-
phoretically separated on a 1.2% agarose/1.1% formaldehyde gel,
and transferred to a Hybond membrane (Amersham Pharmacia
Biotech) by vacuum blotting in 20
 
3
 
 SSC. The RNA was cross-
linked to the membrane by UV fixation (Stratalinker
 
®
 
; Strat-
agene) for 1 min. A 
 
32
 
P-labeled cDNA probe was generated from
the cloned PCR product (80 ng plasmid) by amplification (con-
ditions as described above) in the presence of [
 
a
 
-
 
32
 
P]dCTP (50
 
m
 
Ci). Hybridization and stripping of Northern blots were carried
out according to standard procedures (19). After stripping the
membranes, a loading control with 
 
32
 
P-labeled 
 
b
 
-actin cDNA
probe was performed. The blots were exposed to a PhosphorIm-
ager
 
®
 
 screen and analyzed with ImageQuant
 
®
 
 software (Molecu-
lar Dynamics).
 
Reverse Transcription PCR.
 
Total RNA was prepared from
cultured cell lines using TRIZOL (Life Technologies) and
cDNA synthesized from 1 
 
m
 
g of total RNA. Reverse transcrip-
tion (RT) was performed in a 20 
 
m
 
l volume of 1
 
3
 
 first strand
buffer, 10 mM DTT, 500 
 
m
 
M of each dNTP, 200 U of Super-
Script II Reverse Transcriptase (all reagents from Life Technolo-
gies), 500 ng of oligo-dT, and 20 U of RNasin (Promega). RNA
and primer were heated at 70
 
8
 
C for 5 min and immediately
chilled on ice before the addition of RNasin, first strand buffer,
DTT, dNTPs, and reverse transcriptase. Samples were incubated
at 42
 
8
 
C for 30 min, and the reaction was stopped by incubation
at 94
 
8
 
C for 5 min.
As endogenous RNA control, we selected the porphobilino-
gen deaminase/hydroxymethylbilane synthase (PBGD) gene (20)
because no corresponding retropseudogenes exist so far in con-
trast to 
 
b
 
-actin, glyceraldehyde 3-phosphate dehydrogenase,
and hypoxanthine ribosyltransferase (21). The oligonucleotides
used in PCR amplification were as follows: profilin P1 (sense
strand in exon 1), 5
 
9
 
-CGAGAGCAGCCCCAGTAGCAGC-3
 
9
 
;
profilin P2 (antisense strand in exon 2), 5
 
9
 
-ACCAGGACAC-
CCACCTCAGCTG-3
 
9
 
, resulting in a 179-bp PCR product;
and PBGD-S (sense strand in exon 1), 5
 
9
 
-TGTCTGGTAACG-
GCAATGCGGCTGCAAC-3
 
9
 
, resulting in a 126-bp PCR
product. PCR was performed in a 20-
 
m
 
l volume of 1
 
3
 
 PCR
buffer, 200 
 
m
 
M of each dNTP, 1.5 U Taq DNA polymerase (all
reagents from PerkinElmer), and 0.5 
 
m
 
M of primers with 2 
 
m
 
l
cDNA. PCR consisted of an initial denaturation step at 95
 
8
 
C for
3 min, followed by 30 cycles at 95
 
8
 
C for 20 s, annealing at 60
 
8
 
C
for 15 s, and extension at 72
 
8
 
C for 30 s in each cycle using a
GeneAmp PCR System 9600 (PerkinElmer). PCR products
were separated on 3:1 NuSieve agarose gels (FMC Bioproducts)
and visualized by ethidium bromide staining. The ImageQuant
 
®
 
Software was used for analysis.
 
Sequence Analysis.
 
The cloned PCR fragments were se-
quenced using an ABI DNA sequencer, T7 or M13 reverse
primer, and the Dye Terminator Cycle Sequencing kit according
to the manufacturer’s protocol (PE Biosystems). A minimum of
two independent clones of each PCR fragment was sequenced
to exclude that different PCR products with the same length
were excised from the polyacrylamide gel. The cDNA sequences
were compared with sequences in the EMBL/GenBank/DDBJ
database, using FASTA and BLASTN.
 
Preparation of Cell Lysates and Western Blot Analysis.
 
Cell ly-
sates were prepared as described (22). SDS-PAGE and Western 
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immunoblot analysis were performed according to standard pro-
cedures. The monoclonal profilin 1 antibody, 2H11 (23), was
used at a 1:10 dilution, and an mAb against 
 
b
 
-actin (Sigma-Aldrich)
was used at a 1:2,000 dilution. After incubation with peroxi-
dase-conjugated anti–mouse IgG antibody (1:10,000 dilution;
Promega), immunoreactive bands were detected by the enhanced
chemiluminescence method (Amersham Pharmacia Biotech). For
quantitation of profilin 1 content, the gel evaluation system
E.A.S.Y. (Herolab) was used. For CAL51 and its derivatives, pro-
filin 1 was expressed as relative value normalized to the 
 
b
 
-actin
content. For the comparison between the tumorigenic breast
cancer lines and their normal counterparts, profilin 1 was ex-
pressed as absolute value per standard amount of total protein.
Regression constants obtained with standard profilin 1 curves
were in the range of 0.97–0.99.
 
Immunofluorescence Analysis.
 
Cells were grown on glass cover-
slips for 24 h before fixation in 4% formaldehyde for 20 min, and
subsequent extraction with 0.2% Triton X-100 for 10 min. Next,
the samples were incubated for 1 h at room temperature in a
moist chamber with 2H11 (23). Goat anti–mouse IgG coupled to
tetramethylrhodamine-B-isothiocyanate (TRITC; Dianova) was
used as secondary antibody and phalloidin-FITC for labeling of
F-actin. The cells were examined with a conventional light mi-
croscope equipped with epifluorescence (Axiophot; ZEISS). All
photographs were taken with the same exposure time.
 
cDNA Cloning.
 
PFN1 cDNA was amplified from a CAL/17-5
cDNA library by PCR using PFN1-specific primers 5
 
9
 
-GAG-
GCAGCTCGAGCCCAGTC-3
 
9 
 
and 5
 
9
 
-AAATGGTTTGT-
GTGTGTATG-3
 
9
 
 (sequence data available from EMBL/Gen-
Bank/DDBJ under accession no. J03191, and see reference 7).
The cycling parameters were as follows: 95
 
8
 
C for 5 min, fol-
lowed by 94
 
8
 
C for 30 s, 60
 
8
 
C for 30 s, and 72
 
8
 
C for 45 s for a to-
tal of 35 cycles and an extension at 72
 
8
 
C for 10 min. The purified
546-bp fragment was cloned into the pCRII vector, excised with
EcoRI, and recloned into the eukaryotic expression vector
pcDNA3 (Invitrogen), which contains the neo
 
R
 
 gene as a selec-
tion marker, resulting in the plasmid pcDNA3-P. Orientation
and integrity of the vector construct were confirmed by sequenc-
ing in both orientations.
 
Transfection of CAL51 Cells with PFN1 cDNA.
 
Purified plas-
mid DNAs (pcDNA3-P and pcDNA3; 2 mg in each case) were
transfected into CAL51 cells using 60 mg Lipofectin according to
the manufacturer’s instructions (Life Technologies). Selection
with 800 mg/ml G418 started 48 h after transfection. After 2–3
wk, G418-resistant clones were picked and further propagated in
the selective medium. Expression analysis of several clones was
performed by RT-PCR. RNA isolation and conditions for RT
using an oligo-dT17 primer were as above. PCR was carried out
as described above, but 2.0 ml first strand cDNA was used as tem-
plate, and b-actin–specific primers (0.5 mM) were used addition-
ally (duplex PCR). Only 20 cycles were performed. PCR prod-
ucts were separated on a 2% agarose gel, visualized by ethidium
bromide staining, and evaluated by using the ImageQuant® soft-
ware.
In Vitro Growth Assays. Cell growth rates on plastics and col-
ony-forming ability in soft agar were determined as described
previously (2). For the extracellular matrix assay, cells were sus-
pended and adjusted to 8.4 3 105 cells per ml culture medium.
Then, samples of 60 ml cells were mixed gently with 300 ml
Matrigel (Collaborative Biomed, Inc.) at 48C and plated on 24-
well plates. Mixtures were overlaid after gelling with 0.7 ml cul-
ture medium containing 2% FBS. Cultures were kept at 378C in
a humidified atmosphere containing 5% CO2.
The matrigel cultures were fixed in phosphate-buffered 2%
paraformaldehyde/12.5% glutaraldehyde in 0.09 M sucrose over-
night, cooled for 5 min in isopentane (2358C), and stored at
2808C. After a short postfixing in 5% buffered formalin, the cul-
tures were treated in the conventional manner for embedding in
paraffin, cut in 5-mm slices, and stained with hematoxylin and
eosin.
Cell Spreading. Spreading of CAL51, microcell hybrids,
PFN1-transfected CAL51 clones, and MCF-10A was monitored
by seeding the cells onto glass coverslips. They were allowed to
adhere for 30 min before fixation and processing for fluorescence
microscopy. According to their distinct differences in surface area
and morphology, the cells were divided into two groups: small,
round cells showing no obvious sign of spreading (group 1), and
flat cells in the process of spreading or already well spread (group
2). Monitoring the proportion of group 1 to group 2 cells in a
given time point after seeding serves as a measure of their spread-
ing velocity. At least 500 cells per coverslip were counted in 4 in-
dependent experiments.
Tumorigenicity Test. Suspensions of 106 and 105 cells, respec-
tively, in a volume of 0.2 ml of serum-free culture medium were
injected subcutaneously into 5–8-wk-old female immune-defi-
cient nude mice (BlnA:NMRI-nu/nu). Tumor volumes were es-
timated as described previously (24). Cell populations were con-
sidered to be nontumorigenic if no tumors were detected after 3
mo postinjection.
Immunohistochemical Analysis. Formalin-fixed, paraffin-embed-
ded tissue blocks of 40 cases of invasive breast cancer were re-
trieved from pathology archives. Immunostaining was performed
essentially as described (25). In short, 3-mm sections were sub-
jected to heat-induced antigen retrieval and subsequently incu-
bated with purified mouse mAb 2H11. Antigen–antibody com-
plexes were visualized using biotinylated anti–mouse Ig,
streptavidin–alkaline phosphatase conjugate (Jackson ImmunoRe-
search Laboratories), and Fast Red chromogenic substrate
(Sigma-Aldrich). Cellular distribution and intensity of PFN1 ex-
pression were scored in comparison with nonneoplastic mam-
mary epithelia and/or leukocytes in the same section.
DNA Isolation and Mutation Analysis. DNA was isolated from
washed trypsinized cells or from blood as control using the
QIAamp tissue and blood kits (Qiagen). PCR products covering
exons 1–3, flanking intronic sequences, and the 59 end of the
PFN1 gene were sequenced with the DyeDeoxy Terminator Cy-
cle Sequencing kit (PE Biosystems) in both directions and run
onto an ABI 377 automatic sequencer.
Results
CAL51 Cells Express Low Levels of PFN1 mRNA and Pro-
tein, and Show a Low Degree of Microfilament Organization.
To monitor possible differences in mRNA levels between
tumorigenic CAL51 breast cancer cells and cells from a
matched nontumorigenic CAL/17-5 microcell hybrid
clone, differential display was performed in duplicate on
total RNA from both cell lines. A representative gel using a
single primer set is shown in Fig. 1. Several mRNAs were
reproducibly differentially expressed. A series of 164 partial
cDNAs that displayed a significantly high ratio of differen-
tial expression was selected. To date, 40 have been used as
probes in Northern blot analysis. For 12 of the 40 cDNAs
analyzed, the results of the differential display experiments1678 Suppression of Tumorigenicity in Breast Cancer Cells by Profilin 1
were corroborated by this method. Some of these cDNAs
displayed important homology with previously cloned hu-
man genes (e.g., Sp17 gene, apolipoprotein J gene; our un-
published data). One of these genes reproducibly exhibited
a strongly reduced transcription in CAL51 cells compared
with the CAL/17-5 hybrid cells. A FASTA search for se-
quence homology revealed 98.8% sequence homology to
that of human PFN1. Therefore, these results indicate that
CAL51 and its microcell hybrid derivative differ substan-
tially in the expression of PFN1 mRNA.
PFN1 protein expression in CAL51 and microcell hy-
brid cells was then examined by Western blot and immu-
nocytochemistry using the profilin 1–specific antibody
2H11, which recognizes profilin 1 in a wide variety of mam-
malian cells (23). The Western blot analysis showed that the
profilin 1 level in CAL51 cells is low compared with the mi-
crocell hybrid clone CAL/17-5 (Fig. 2 B). When normal-
ized to the b-actin level, an almost 14-fold difference be-
tween CAL51 and CAL/17-5 was found (Fig. 2 C).
These results were also reflected in the images obtained
for both cell types by immunofluorescence. As demon-
strated in Fig. 3, the profilin 1–specific stain was very low in
the parental CAL51 cells (Fig. 3, top). In contrast, CAL/17-5
cells displayed a moderate to strong reactivity for profilin 1
(Fig. 3, second from top) visible as a diffuse cytoplasmic
stain and a distinct concentration in the nucleus. The strong
nuclear profilin 1 signal is seen in many cell types after
formaldehyde fixation (23). Similar staining pictures were
also obtained with other microcell hybrid clones (data not
shown). Thus, Western blot and immunofluorescence both
demonstrated a low abundance of profilin 1 in CAL51, and
a much higher level in the microcell hybrid CAL/17-5.
The differences in PFN1 expression seen in immunoflu-
orescence were paralleled by conspicuous differences in the
actin filament organization: whereas CAL51 cells displayed
thin microfilament bundles and short F-actin aggregates
distributed throughout the cytoplasm (Fig. 3, top), CAL/
17-5 cells showed bundling of actin filaments into thick
stress fibers and/or peripheral belts (Fig. 3, second from
top). An organization of the actin filaments in peripheral
belts is typical for normal epitheloid cells, as for example
the breast epithelial cell line MCF-10A (Fig. 3, bottom;
reference 23).
The PFN1 Gene Shows Sequence Variations in CAL51
Cells Compared with A9(neo17) Cells and Lymphocytes. To
determine whether the low PFN1 mRNA and protein ex-
pression in CAL51 reflects a mutated gene, we screened for
mutations within the PFN1 gene in both CAL51 and the
microcell donor A9(neo17). The three PFN1 exons, as
well as 923 bp from the 59 genome region, were se-
quenced. For A9(neo17), no differences in the PFN1 gene
were found compared with the sequence present in human
lymphocytes. For CAL51, sequence variations were de-
tected in exon 3, in the 39 untranslated region, and in the
59 region of the PFN1 gene. The homozygous alteration in
exon 3, C334T, did not result in an amino acid substitu-
tion. A heterozygous deletion (645delT) in the 39 untrans-
lated gene region is not expected to have major effects on
structure or function of the protein product. In contrast,
the homozygous alteration (A-773G) within the 59 pro-
moter region might result in a different binding behavior of
specific transcription factors, and therefore may lead to
consequences on protein translation; however, in the
present case, this is not proven.
Figure 1. (A) Differential dis-
play of the mRNA profiles of
CAL51 breast cancer cells ver-
sus CAL/17-5 microcell hybrid
cells. The indicated RT-PCR
product shows a high density
band in the CAL/17-5 lane. The
PCR product was identified as
part of PFN1 cDNA by compar-
ison with database sequences.
(B) Northern hybridization of
the excised and reamplified
PCR fragment confirmed the
differential expression. (C) Us-
ing a computer program, the
PFN1 mRNA values were stan-
dardized taking into account the
b-actin values. The sum of all
PFN1 mRNA values was set to
100. 75% fall on CAL/17-5 and
25% on CAL51.
Figure 2. Western blot analysis of b-actin (A) and profilin 1 (B) in
CAL51 (lane 1), the microcell hybrid clone CAL/17-5 (lane 2), the stable
PFN1 transfectants CAL/P-23 (lane 3), and CAL/P-25 (lane 4). b-actin
and profilin 1 were detected with the respective mAbs. The depicted strips
were taken from the same gel. The relative (rel.) profilin 1 content is the
ratio of the amount of profilin 1 in CAL51 microcell hybrids and transfec-
tants, respectively, to the profilin 1 amount in CAL51 cells, normalized to
the b-actin band and evaluated by a blot evaluation program (C).1679 Janke et al.
In the microcell hybrid CAL/17-5, both CAL51 and
A9(neo17) PFN1 gene sequences were detected (heterozy-
gous for C334T). This finding confirms that the PFN1
gene is indeed present on the transferred chromosome in
CAL/17-5.
PFN1 cDNA Transfection into CAL51 Mimics Profilin 1
Level and Distribution In the Microcell Hybrids. To charac-
terize the correlation between profilin 1 levels and the
properties of CAL51, CAL51 cells were transfected with
the vector pcDNA3-P containing full-length PFN1 cDNA
and the neomycin acetyl transferase gene (neoR) conferring
resistance to the aminoglycoside G418. Resistant colonies
were selected, and cell clones were isolated and further
propagated in medium containing G418. PFN1 expression
in the different clones obtained was again examined by
Western blot and immunostaining using the antibody
2H11. In two selected clones, CAL/P-23 and CAL/P-25,
PFN1 expression was substantially increased (5.1- and 2.4-
fold, respectively, normalized to b-actin) compared with
CAL51 (Fig. 2). Consistent with the Western blot data,
immunofluorescence on cells of these two clones showed
moderate to strong profilin 1 staining, and the profilin 1
distribution was similar to that obtained for the microcell
hybrid clone CAL/17-5 (Fig. 3). In accordance with the
PFN1 expression, the actin filament distribution in CAL/
P-23 and CAL/P-25 was similar to that observed for the
microcell hybrid clone: the cells displayed well-formed
stress fibers and epitheloid peripheral belts (Fig. 3), a mor-
phology also seen in MCF-10A cells (Fig. 3, bottom).
Expression of Exogenous PFN1 Suppresses Transformed and
Tumorigenic Properties of CAL51. Previously, we demon-
strated that microcell hybrids obtained after transfer of
chromosome 17 into CAL51 cells showed a clearly reduced
growth rate compared with CAL51 cells (2). In accordance
with these results, the PFN1-transfected clones CAL/P-23
and CAL/P-25 showed a marked reduction in growth rate
compared with the parental cells and CALX8, a cell line
derived from CAL51 cells mock-transfected with the con-
trol plasmid pcDNA3 (Fig. 4 A).
Anchorage-independent growth, a generally accepted
indicator of the transformed phenotype in vitro (26), was
Figure 3. Fluorescence analysis of the actin cytoskeleton of CAL51,
CAL/17-5 microcell hybrids, CAL/P-23 and CAL/P-25 PFN1 transfec-
tants, and breast epithelial cells MCF-10A. Cells were double-stained
with the profilin 1 mAb 2H11 and TRITC-coupled anti–mouse IgG,
and with phalloidin-FITC for F-actin (phall). All pictures were taken
with the same exposure times. Bar, 20 mm.
Figure 4. In vitro growth properties of
CAL51 and derivatives. (A) Growth curves
of CAL51, mock-transfected CAL51 cells
(CALX8), and the PFN1-transfected clones
CAL/P-23 and CAL/P-25. (B) Growth of
the same cell lines in soft agar. 5 3 104 cells
were plated per dish. 100% (CAL51) 5 4.4 3
102 colonies. The data points reflect the
means of three independent experiments.1680 Suppression of Tumorigenicity in Breast Cancer Cells by Profilin 1
tested by plating the cells in semisolid agar medium. The
PFN1-transfected clones CAL/P-23 and CAL/P-25 showed
a clearly reduced colony-forming capacity compared with
CAL51 and CALX8 cells (Fig. 4 B). In this assay, the level
of reduction in the colony-forming ability varied for differ-
ent transfected clones between 19.7 and 38.6% compared
with 100% colony-forming ability for CAL51 cells. There
was no partial suppressive effect of the PFN1-transfected
clones compared with the CAL/17-5 cells, and growth on
plastic and in soft agar was comparable between these cell
lines.
We also found a clear correlation between the profilin 1
content and the spreading behavior of CAL51 and its de-
rivatives. The spreading velocity determines cell contact
formation. Thus, in general, normal epithelial cells are ex-
pected to spread faster than tumorigenic cells. Inspection of
the shape of CAL51, CAL/17-5, CAL/P-23, CAL/P-25,
and MCF-10A cells shortly after seeding permitted the as-
signment of these cells to two distinct categories: round,
compact cells and flat, moderately or already well-spread
cells (Fig. 5 A). At 30 min after seeding, a high proportion
(60%) of the CAL51 cells belonged to the first group, while
the majority of the CAL51 derivatives with a higher profi-
lin 1 level were already in group 2 (Fig. 5 B) to the same
extent as the normal breast epithelial cell line MCF-10A.
To detect in vivo architectural differences between nor-
mal and tumorigenic cells, we used a three-dimensional ex-
tracellular matrix assay (27). CAL51 and CALX8 cells, the
microcell hybrid CAL/17-5, and the PFN1-transfected
clones, CAL/P-23 and CAL/P-25, were plated in Matrigel
and compared with respect to their pattern of growth and
differentiation to an equal number of MCF-10A cells, a
nontransformed breast epithelial line. In each case, initially
after plating, the cells were distributed evenly over the sur-
face of the well. After 2–3 wk of incubation in Matrigel
cells of the transfected clones, CAL51 cells showed a com-
pletely different morphology. The CAL51 cells had formed
large colonies with smooth boundaries (Fig. 6 A). A similar
result was obtained for the CALX8 control cells (Fig. 6 B).
In contrast, the nontransformed breast epithelial cell line
MCF-10A formed structures reminiscent of glandular orga-
nization. Large, duct-like structures were seen intercon-
necting multicellular spheres and other aggregates, which
displayed fine filamentous, partially branching, projections
(Fig. 6 C). Both PFN1-transfected clones, CAL/P-23 and
CAL/P-25 (Fig. 6, E and F), as well as the microcell hybrid
clone CAL/17-5 (Fig. 6 D), grew in a pattern similar to
MCF-10A but distinct from that of CAL51. They also
formed structures reminiscent of the mammary alveolar
ductal system. Histological sections (Fig. 6, A9–F9) con-
firmed the alveolar organization: many of these spheres
were hollow, and the bordering cells displayed an epithe-
lioid morphology. Such structures were never seen with the
CAL51 cells. These data suggest that an elevated profilin 1
Figure 5. Spreading of CAL51, the microcell hybrid CAL17-5, the
PFN1 transfectants CAL/P-23 and CAL/P-25, and the breast epithelial
cell line MCF10-A. Cells were allowed to adhere to coverslips for 30
min (B), before fixation and phalloidin staining. As seen in A, the cells
could be assigned to two groups that differed in the surface area occupied
and in their morphology (designated 1 and 2). The proportion of cells in
each group was determined. The diagram in B shows the result of 4 in-
dependent experiments with at least 500 counted cells per coverslip. Bars
indicate SDs.
Figure 6. Growth of CAL51 (A, A9), the mock-transfected control
CALX8 (B, B9), the mammary epithelial cell line MCF-10A (C, C9), the
microcell hybrid CAL/17-5 (D, D9), and the PFN1 transfectants CAL/
P-23 (E, E9) and CAL/P-25 (F, F9) in Matrigel. Total cultures of the dif-
ferent cell types (A–F) and hematoxylin and eosin–stained histological
sections (A9–F9) are shown. Bars: (single) 100 mm; (double) 20 mm.1681 Janke et al.
level directs the CAL51 cells towards a closer to normal
phenotype.
A High Profilin 1 Content Reduces Tumorigenicity of
CAL51. The low PFN1 expression in CAL51 breast can-
cer cells prompted us to examine the consequences of
forced expression of PFN1 on the tumorigenic properties
of these cells. CAL51 cells, the microcell hybrid clone
CAL/17-5, and the PFN1-transfected CAL/P-23 and
CAL/P-25 clones were injected subcutaneously into 5–8-
wk-old nude mice. Formation of tumors was recorded
over a period of .60 d (Table I). CAL51 cells produced
progressively growing tumors that were palpable within
,1 mo when 106 cells were inoculated per animal. In con-
trast, the clones expressing exogenous PFN1 did not pro-
duce palpable tumors even 2 mo after injection, at which
time the CAL51-injected animals had all developed tu-
mors. To ensure that the neomycin resistance gene was not
responsible for the suppression of the neoplastic phenotype,
G418-resistant CALX8 cells were injected into nude mice.
These cells were tumorigenic at rates comparable to those
of CAL51 (data not shown), indicating that the suppressed
phenotypes cannot be attributed to the expression of the
neoR gene.
Here (Table I), and in earlier experiments (2), we could
demonstrate that the tumorigenicity as originally observed
in CAL51 cells was completely suppressed when CAL/17-5
and other CAL/17 microcell hybrids were injected into
nude mice.
Low Profilin 1 Contents Are Seen In a Variety of Human
Breast Cancer Cell Lines and Human Breast Cancer Tissue.
Next, we investigated whether the low profilin 1 content
of CAL51 cells, as described here, might be a property
unique to this particular cell line. By RT-PCR, we ana-
lyzed the PFN1 mRNA level of three human breast cancer
cell lines in comparison with the two nontumorigenic epi-
thelial cell lines, H184 and MCF-10A, and the CAL/17-5
microcell hybrid, respectively. As seen in Fig. 7, the PFN1
mRNA content of the nontumorigenic cell lines and the
CAL/17-5 microcell hybrids showed PFN1 mRNA levels
approximately threefold of the values obtained for the tu-
morigenic lines. Furthermore, by quantitative immunoblots,
we analyzed the profilin 1 content of four human breast
cancer cell lines in comparison with two nontumorigenic
epithelial lines. As seen in Fig. 8 (A and C), the profilin 1
content varied slightly between the tumorigenic lines.
Table I. Tumorigenicity of CAL51, PFN1-transfected CAL51 Clones, and Microcell Hybrid CAL/17-5 Cells
Tumor volume (mm3)*
Cell line
Inoculated cells 
per animal
Mice with tumor/
mice injected 1 wk‡ 23456 7891 0
CAL51 106 4/4 2 15 144 240 301 368 653 701 846 918
105 4/4 0 1 5 81 90 180 322 404 553 746
CAL/P-23 106 1/2 0 0 0 0 0 0 10 32 63 147
105 0/2 0 0 0 0 0 0 0 0 0 0
CAL/P-25 106 2/5 0 0 0 0 0 0 25 38 62 62
105 0/3 0 0 0 0 0 0 0 0 0 0
CAL/17-5 106 0/3 0 0 0 0 0 0 0 0 0 0
105 0/3 0 0 0 0 0 0 0 0 0 0
*In case of tumor take 4/4: mean values for four animals are represented; tumor take 1/2: value for the animal showing tumor growth is represented; 
tumor take 2/5: mean values for two animals are represented.
‡Week after injection, 1–10.
Figure 7. RT-PCR analysis of PFN1 and PBGD expression in H184
(lane 1), MCF-10A (lane 2), CAL/17-5 (lane 3), CAL51 (lane 4), R103
(lane 5), and T47D cells (lane 6). The relative (rel.) PFN1 mRNA con-
tent is the ratio of the amount of PFN1 mRNA in the cell lines to the
amount in CAL51 cells normalized to the PBGD bands and evaluated by
a computer program.1682 Suppression of Tumorigenicity in Breast Cancer Cells by Profilin 1
Among those, CAL51 did not show an extremely low level.
On the other hand, the two nontumorigenic lines investi-
gated, H184 and MCF-10A, showed consistently higher
values, with profilin 1 contents z1.5–2-fold of the values
determined for the tumor lines. In contrast, the actin con-
tent of tumorigenic and nontumorigenic lines was approxi-
mately the same (data not shown). Although preliminary,
these data indicate that there may be a consistent difference
in profilin 1 levels between tumorigenic and nontumori-
genic lines in general, and support the notion that a critical
profilin 1 level is required for tumor suppression.
Intermediate and low profilin 1 levels are found in hu-
man breast cancer tissue. Immunohistochemically normal
lobular and ductal epithelia of the mammary gland show a
heterogeneous pattern of PFN1 expression in which indi-
vidual luminal and basal cells displaying a strong cytoplas-
mic PFN1 expression are scattered between epithelial cells
of intermediate to low levels of expression (Fig. 9 A). This
heterogeneity appears greatly reduced in breast cancers
where the majority of the invasive cells display a uniform
PFN1 expression in their cytoplasm. Compared with non-
neoplastic mammary epithelia and/or leukocytes, PFN1
was found to be expressed at intermediate levels (Fig. 9 B)
in 31 (78%) and at low levels (Fig. 9 C) in 9 (22%) of the
40 breast cancers studied. Interestingly, one case with inter-
mediate PFN1 expression in the primary tumor showed a
low expression in its axillary metastasis (Fig. 9 D).
Figure 8. Western blot analysis (A) showing the profilin 1 content in
relation to total protein in two normal breast epithelial lines (black bars in
C) and four breast cancer lines (gray bars in C). The bars reflect the values
from blots obtained with the profilin 1 antibody 2H11, derived from 10
gels containing protein extracts of all 6 lines. SEs are given in C. A repre-
sentative profilin 1 standard curve is given in B.
Figure 9. Immunohistochem-
ical expression analysis of PFN1
in human mammary tissues. Par-
affin sections were subjected to
heat-induced antigen retrieval,
and subsequently incubated with
purified mouse anti–profilin 1
mAb 2H11. Antigen–antibody
complexes were visualized using a
biotin/streptavidin–alkaline phos-
phatase/Fast Red system. (A)
Normal breast lobule with heter-
ogeneous intermediate and focally
strong expression of PFN1 in the
cytoplasm of basal and luminal
epithelial cells. (B) Invasive mam-
mary carcinoma with homoge-
nous intermediate expression of
PFN1 in the cytoplasm of tumor
cells. (C) Formation of invasive
mammary carcinoma next to a
nonneoplastic lobule. Note the
reduced expression of PFN1 in
the cancer cells and the retained
strong staining of intravascular
leukocytes (bottom right). (D)
LN metastasis of the primary
mammary carcinoma depicted in
B with loss of PFN1 expression in
the metastatic tumor cells. Resid-
ual lymphatic elements retain
their pronounced cytoplasmatic
expression of PFN1. Original
magnifications: (A) 3600; (B)
3400; (C) 3200; and (D) 3600.1683 Janke et al.
Discussion
In this study, differential gene expression was analyzed in an
experimental system consisting of a tumorigenic breast cancer
cell line, CAL51, and a nontumorigenic CAL/17-5 microcell
hybrid, obtained after transfer of human chromosome 17 into
CAL51 cells. Differential display was used to identify the pat-
tern of genetic alterations. The PFN1 gene showed a mark-
edly increased expression in the microcell hybrid clone relative
to the lower level in CAL51 cells. Differential expression of
PFN1 was confirmed by Northern and Western blot analysis,
and by immunostaining. The PFN1 gene was mapped to
chromosome region 17p13.3 (7), which is the particular part
of chromosome 17 identified in the microcell hybrid clones
after chromosomal transfer into CAL51 cells (2).
Having identified PFN1 mRNA levels as one of the ma-
jor differences between CAL51 and its microcell hybrid
derivatives, we directly challenged the role of PFN1 ex-
pression on the morphological and tumorigenic properties
of these breast cancer cells by transfer of PFN1 cDNA. The
obtained stable cell lines behaved quite similar to the mi-
crocell hybrid clones in the following ways: (a) they
showed a higher PFN1 expression, which was correlated
with reduced growth rates and a more sophisticated organi-
zation of the actin cytoskeleton; (b) they spread much faster
on glass, indicating better adhesion properties; (c) they dis-
played an improved anchorage dependence and the capac-
ity to form epitheloid structures; and (d) they were much
less tumorigenic in nude mice. Therefore, the sole eleva-
tion of the profilin 1 level drives CAL51 cells towards a
more normal epithelial differentiation.
For several tumorigenic and nontumorigenic breast epi-
thelial lines, we found a consistently lower profilin 1 con-
tent in the former. These differences did not exceed a fac-
tor of three, and more detailed investigations are needed to
further substantiate these data. However, they indicate that
a critical level of profilin 1 must be exceeded to effect tu-
mor suppression. Similarly low expression of PFN1 is im-
munohistochemically apparent in .20% of invasive breast
cancers. It remains to be seen whether the profilin 1 con-
tent reflects stages in tumor progression or marks particular
biological and prognostic subsets of mammary carcinoma.
On the other hand, a substantial surplus in profilin 1, as
found in CAL/17-5 and CAL/P-23, obviously does not
interfere with normal cellular functions. An increase in mi-
crofilament organization and cell adhesion, as shown here,
has also been reported for other cell types overexpressing
PFN1 by factors of two to eight (28, 29).
Profilins are ubiquitous, 12–15-kD proteins identified in
all eukaryotic systems examined to date, including yeast,
amebae, vertebrates, and plants (8, 9, 30). Many organisms
contain two genes, PFN1 and PFN2, of which PFN1,
widely expressed, is indispensable for normal cellular func-
tions (9). Profilins are thought to regulate signal-dependent
actin polymerization (9). The involvement of the actin-
based cytoskeleton in many cellular functions, including
cell adhesion and motility, growth and cytokinesis, signal
transduction, and the establishment and maintenance of cell
morphology relies on different states of supramolecular or-
ganization, executed by actin-binding proteins (31, 32).
Conversely, tumorigenicity, and in particular metastatic ca-
pacity, has been frequently correlated with a particular or-
ganization of the microfilament system (33, 34). In general,
it was assumed that stable microfilament bundles and cell
matrix contacts are correlated with normal phenotyes of
cells and tissues, while transformation to malignancy, as for
example caused by tumor viruses, is accompanied by re-
duced expression of proteins such as tropomyosin (35),
a-actinin (36), and vinculin (37, 38). These proteins, which
stabilize, bundle, or cross-link actin filaments and thus me-
diate the highly ordered microfilament organization essen-
tial for regulated growth, adhesion, and differentiation,
have been classified as tumor suppressor proteins in a vari-
ety of experimental systems.
For profilins, which are believed to be primarily engaged
in actin dynamics, tumor suppressor activity has not been
described so far. It has been shown that overexpression of
profilin in mammalian cell culture cells leads to a stabiliza-
tion of actin filaments (29, 39), which may be directly
caused by the actin polymerization-promoting activity of
profilins. Furthermore, endothelial cells overexpressing
profilin display increased adhesion to the substratum (28),
another feature that has been correlated with a nonmalig-
nant phenotype of cells. However, it is conceivable that the
effects of an imbalance of actin-associated proteins on tu-
morigenicity are not directly linked to their mode of actin
organization, but to their role in signal transduction to the
actin cytoskeleton. In this context, it is noteworthy that
gelsolin, another actin-binding protein involved in actin
filament dynamics, has also been described as a tumor sup-
pressor protein (40). Gelsolin and profilins both bind to the
acidic phospholipid phosphatidylinositol 4,5-bisphosphate
(PIP2), a well-characterized mediator in several signal trans-
duction pathways (31, 32), and are thus both considered im-
portant connectors at the cross-roads of PIP2-dependent sig-
nal transduction (9, 41). For profilins, additional links to
signal transduction pathways have to be considered. Several
polyproline-rich proteins have now been identified as ligands
for the poly-l-proline binding site on these small proteins in
mammals. In this context, the vasodilator-stimulated phos-
phoprotein (VASP), which is a substrate for cAMP/cGMP-
dependent kinases (16), and p140mDia, a formin-related
protein comprising a rho-GTPase binding site in addition to
a profilin-binding motif (15), should be mentioned. More
recently, profilins have been identified as nuclear constitu-
ents and ligands for proteins involved in transcription and
RNA processing (42). A low profilin 1 content, as indicated
by our findings for the tumor cells described here, might
therefore result in a cascade of consequences exceeding by
far a simple reduction in profilin–actin complexes, leading to
transformed properties and tumorigenicity.
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